Amphastar Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M |
| Cost of revenue | $363.8M | $358.1M | $293.3M | $250.1M | $238.0M |
| Gross profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M |
| Research and development | $85.8M | $73.9M | $73.7M | $74.8M | $60.9M |
| Operating expenses | $215.7M | $168.4M | $154.1M | $141.4M | $129.9M |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M |
| Interest expense | $25.5M | $30.3M | $27.2M | $1.8M | $885,000 |
| Pretax income | $123.6M | $189.8M | $171.4M | $116.0M | $84.1M |
| Income tax expense | $25.5M | $29.7M | $31.8M | $23.5M | $20.6M |
| Net income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M |
| Balance Sheet | |||||
| Cash and equivalents | $170.2M | $151.6M | $144.3M | $156.1M | $126.4M |
| Current assets | $636.0M | $534.1M | $489.6M | $378.3M | $318.1M |
| Total assets | $1.6B | $1.6B | $1.5B | $742.0M | $671.5M |
| Current liabilities | $158.2M | $173.8M | $225.4M | $94.9M | $103.8M |
| Total liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M |
| Stockholders' equity | $788.8M | $732.3M | $639.4M | $528.7M | $445.5M |
| Cash Flow Statement | |||||
| Cash from operations | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M |
| Depreciation and amortization | $31.6M | $28.2M | $25.7M | $12.6M | $10.2M |
| Stock-based compensation | $27.3M | $24.4M | $20.2M | $17.9M | $18.7M |
| Capital expenditure | $34.9M | $41.0M | $38.2M | $24.0M | $27.5M |
| Free cash flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M |
| Share repurchases | $75.6M | $85.5M | $58.1M | $39.9M | $28.9M |
Shares outstanding 44.1M · Free float 75.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.